# Ginkgo Bioworks

Type: Company (DNA)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/ginkgo-bioworks
Canonical HTML page: https://getfinancebrief.com/entity/ginkgo-bioworks

## Timeline

- **2026-03-15**: Divestiture Completion — Projected timeline for the formal separation of non-core biosecurity assets.
- **2026-02-27**: Earnings Release — Ginkgo reports a $0.38 EPS beat and releases full-year 2025 financial results.
- **2026-02-27**: Strategic Pivot — Company announces the divestiture of its biosecurity business and focus on Autonomous Labs.
- **2026-02-25**: Pre-Earnings Analysis — Market analysts provide insights into Ginkgo's upcoming results amid high expectations for cost-cutting updates.

## Recent coverage (1 stories)

### Ginkgo Bioworks Surprises Markets with Significant $0.38 EPS Earnings Beat
2026-02-27 03:43:42 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Ginkgo Bioworks (NYSE: DNA) outperformed analyst expectations by $0.38 EPS in its latest quarterly report, signaling a potential shift in the company's financial trajectory. The results suggest that the synthetic biology leader's cost-cutting measures and platform scaling are beginning to deliver tangible bottom-line improvements.
Full story: https://getfinancebrief.com/story/ginkgo-bioworks-dna-earnings-beat-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.